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According to our model of the regulation of appetitive-searching vs. distress-avoiding
behaviors, the motivation to display these essential conducts is regulated by two parallel
cortico-striato-thalamo-cortical, re-entry circuits, including the core and the shell parts
of the nucleus accumbens, respectively. An entire series of basal ganglia, running from
the caudate nucleus on one side, to the centromedial amygdala on the other side,
controls the intensity of these reward-seeking andmisery-fleeing behaviors by stimulating
the activity of the (pre)frontal and limbic cortices. Hyperactive motivation to display
behavior that potentially results in reward induces feelings of hankering (relief leads to
pleasure). Hyperactive motivation to exhibit behavior related to avoidance of misery
results in dysphoria (relief leads to happiness). These two systems collaborate in a
reciprocal fashion. In clinical depression, a mismatch exists between the activities of
these two circuits: the balance is shifted to the misery-avoiding side. Five theories have
been developed to explain the mechanism of depressive mood disorders, including the
monoamine, biorhythm, neuro-endocrine, neuro-immune, and kindling/neuroplasticity
theories. This paper describes these theories in relationship to the model (described
above) of the regulation of reward-seeking vs. misery-avoiding behaviors. Chronic stress
that leads to structural changes may induce the mismatch between the two systems.
This mismatch leads to lack of pleasure, low energy, and indecisiveness, on one
hand, and dysphoria, continuous worrying, and negative expectations on the other
hand. The neuroplastic effects of monoamines, cortisol, and cytokines may mediate
the induction of these structural alterations. Long-term exposure to stressful situations
(particularly experienced during childhood) may lead to increased susceptibility for
developing this condition. This hypothesis opens up the possibility of treating depression
with psychotherapy. Genetic and other biological factors (toxic, infectious, or traumatic)
may increase sensitivity to the induction of relevant neuroplastic changes. Reversal or
compensation of these neuroplastic adjustments may explain the effects of biological
therapies in treating depression.
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INTRODUCTION
The burden of depression in modern society is enormous.
According to the definition of the often applied criteria of the
American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders (DSM), major depressive disorder
(MDD) is highly prevalent, and patients with MDD are seriously
disabled. In the Dutch NEMESIS-2 study, the lifetime prevalence
of MDD, diagnosed according to DSM-IV criteria (APA, 2000),
was 13.1% for men and 24.3% for women (De Graaf et al., 2010).
This prevalence was measured in 18–64 year-old, ambulatory
Dutch citizens; however, a significant proportion of individuals
experience their first depressive episode after the age of 50
years (i.e., women after menopause and seniors). Therefore,
the risk of experiencing depression over a given lifetime is
probably much higher than the figures imply. This is interesting,
because the lifetime prevalence is far lower for other mental
disorders, including schizophrenia (0.3–1%), bipolar disorder
(1.7% in high income countries), and borderline personality
disorder (1.6%median population prevalence) (APA, 2013). Even
specific anxiety disorders, like panic disorder (3.8%), occur far
less frequently than MDD (De Graaf et al., 2010). This very
high lifetime prevalence of MDD indicates something about its
position in the spectrum of mental disorders, and probably also,
about its pathogenesis.
Depression is a mood disorder, and mood is considered
an emotion. It is sometimes stated that emotions are a
highly developed phenomenon, displayed only by the most
sophisticated organisms on the planet earth; i.e., Homo sapiens.
This observation is typically used as a basis for proposing
that only humans can experience a depressed mood, because
the emotional state of “feeling depressed” is a unique human
quality. Primitive animals are believed to be incapable of feeling
sad or insecure. However, the authors do not agree with this
notion. In fact, upon reviewing the evolution of the vertebrate
forebrain, the conclusion emerged that emotions, like pleasure or
happiness, were among the most primitive modes of perceiving
the environment (Loonen and Ivanova, 2015). Specific cognitive
functions arise from relatively new regions of the cerebral cortex,
and emotions probably arise from phylogenetically old parts of
the brain.
Recently, a new model was presented that distinguished
between two types of cortico-ganglio-thalamo-cortical tracks,
which could regulate intuitive (emotional) and skilled (cognitive)
behaviors. These tracks were called the limbic and extrapyramidal
circuits, respectively (Loonen and Ivanova, 2016a). The
motivation for exhibiting these two types of behaviors was
regulated by two re-entry circuits; including the nucleus
accumbens shell (NAcbS) and the nucleus accumbens core
(NAcbC), respectively. The NAcbS-containing circuit motivated
a display of misery-fleeing behavior; the NAcbC-containing
circuit motivated reward-seeking conduct.
The present study aimed to use this model to interpret
some of the abundant experimental data on the pathogenesis
of depressive disorders. Misery-fleeing and reward-seeking
behaviors constitute essential conducts for every free-moving
animal to maintain life and to produce offspring. Therefore,
the system regulating these behaviors can be traced back
to brain structures of the earliest vertebrate ancestors of
humans (Loonen and Ivanova, 2015). Continuous adequate
functioning of these systems depends upon the ability to
adapt sufficiently to the often changing and sometimes harsh
conditions of living. These requirements of the ever changing
biotope present a great challenge to the system, because it
must constantly adapt its functional capabilities. The biological
mechanisms required to accomplish these adaptations comprise
neurochemical, neuro-endocrine, neuro-immune, and neuro-
physiological components. These mechanisms will be described
here, according to five current theories that postulate different
neurobiological backgrounds that give rise to mood disorders
(Loonen, 2013a). According to one school of thought, the
cumulative burden of this active process of adaptation (i.e.,
allostasis) might result in overload (McEwen, 2012, 2015), and
when the system starts to malfunction, it causes symptoms of
depression. However, it may also be hypothesized that the system
overload results when the adaptation process overshoots the
current needs. This situation will be explained by considering
how humans have changed their habitat over the last two
centuries.
PHILOSOPHICAL STARTING POINTS
Modern humans are currently living under conditions which
are considerably different from our biotope, even compared to
a few centuries ago. We should recognize that our bodily systems
are not intended, and perhaps not very suitable, for keeping
us safe and sound in modern times. In fact, humans are not
supposed to live to ages that are normally observed in current
times. In the year 1600 AD, only about 600 million individuals
existed in the entire world (Loonen, 2012). Until the Middle
Ages, life expectancy after birth was about 25 years (Bocquet-
Appel and Bacro, 1997; Eshed et al., 2004; Nagaoka et al., 2006),
and this increased to 45 years after 1900 AD (Mackenbach
and Looman, 2013). The low life expectancy was probably due
to the large risk of infant mortality, combined with death in
young adulthood from accidents, epidemics, plagues, wars, and
childbirth. Most humans probably died from infectious diseases
(Miller and Raison, 2015). When a person was wounded in
an accident or aggressive attack, the wound was often infected
with bacteria, and serious infections ultimately led to death.
In women, giving birth often caused death, frequently due to
infections. Therefore, it is quite clear that, to survive as an
individual and as a species, humans required a very good immune
system, capable of conquering the many challenges of life under
dangerous circumstances. The chances of staying alive were
probably highest in individuals that could activate this immune
system under all conditions that might foster a wound infection.
Therefore, the immune response can be considered a primary
component of a complex stress response.
At the same time, humans lived in very unhygienic conditions.
However, although dirt harbors a multitude of germs, sustained
exposure to dirt may have represented a survival advantage
(Miller and Raison, 2015). The immune response that defends
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against pathogenic germs—which may eventually have become
commensals—must have been suppressed during normal life,
to prevent immune overactivation to the extent that it caused
damage to the human body. Moreover, the presence of
commensals probably prevented other pathological microbes
from invading and causing serious infections (Miller and
Raison, 2015). In addition, the abundance of dirt, bacteria, and
fungi, prevented the immune system from attacking common
proteins and other macromolecules that can cause allergies
and autoimmune diseases. However, the low prevalence of
autoimmune diseases was also due to genetic selection, because a
child or adult could not survive a serious immunological disease
in ancient times. Therefore, it could be concluded that, currently,
our immune system may be over-reacting and perhaps even
causing more diseases than it fights. One of these diseases might
be depressive disorder.
In present times, clinical depression is so common that
it may not be considered an illness. It could be concluded
from foregoing reflections that, perhaps we should think of
depression as the price humans must pay for improving
the standard of living and for dramatically increasing life
expectancy. Humans possess a multimodal mechanism, which
can adapt the organism’s misery-fleeing and reward-seeking
behaviors to a major extent, when required to deal with
specific challenges. However, survival challenges are no longer
frequently encountered in modern human life. Consequently,
our adaptation mechanisms may be out of place (overshooting
the actual needs) and lead to counterproductive behavior;
for example, exaggerated stress reactions or food/substance
abuse. Continuous anxiety and addiction states are regularly
accompanied by specific mood problems (Koob and Le Moal,
1997; Mineka et al., 1998; Koob and Volkow, 2010; Loonen
et al., 2016). Moreover, we should start with the notion that,
during evolution, when humans were living in a natural habitat,
depression may have been a beneficial mechanism for survival.
Inactivity and hiding are probably good strategies for survival,
when the organism is vulnerable to being killed. Therefore, it
may be more fitting to consider clinical depression a reaction,
like fever, vomiting, or diarrhea, which can improve one’s
chances of staying alive under difficult circumstances. Finally,
the high prevalence of depression may be considered to result
from selection pressure. Although humans may no longer die
from tuberculosis or pneumonia, clearly, other conditions will
cause death in due time. Once we can effectively combat
cardiovascular diseases and cancer, humans will begin to die
from, perhaps, neurodegenerative disorders, like Parkinson’s or
Alzheimer’s disease. Inevitably, all living organisms must die.
Hence, disorders like depression will become more prevalent
and also significantly more life-limiting. This will be evident by
comparing current and future rates of depression using standard
diagnostic criteria, the absence of which unfortunately limits our
ability to track changes in the prevalence of depression prior to
the second half of the twentieth century.
A diametrically opposite view is that depression may be
a valuable mechanism for adapting to current circumstances.
The human way of life is rapidly changing, but we should not
expect the human body to change at the same rate. The process
of adaptation may take time. Throughout history, the human
species has frequently been capable of surviving a changing
environment. Modern humans originated from a small group in
South Kenya about 195,000 years ago (McDougall et al., 2005).
Humans populated the Americas about 18,000 years ago, and
disseminated from the Arctic Ocean to the Argentinean Tierra
del Fuego. Moreover, the human ancestors that invaded Eurasia
about 40,000 years agomust have encountered several of themost
recent glacial periods. Therefore, major adaptations to changing
living circumstances are not unusual for mankind. However, it
should be realized that, in the current era, during only about
two centuries, humans have radically changed their biotope from
a rural to an urban environment, and human life expectancy
has doubled. This rate of change was far greater than any prior
rates of change. These rapid changes may induce unusually
strong adaptation reactions within the human species, which
lead to aberrant activity in the biological processes that control
misery-fleeing and reward-seeking behaviors. As a consequence,
rapid change might result in genetic selection, which, through
a common biological mechanism, ensures the fittest individuals
can predominate.
Hence, several potential mechanisms may explain why
depression is currently highly prevalent. Depression may be
considered an aberration of a mechanism that originally favored
survival (retreat from unfamiliar or threatening circumstances),
or it may be a necessary mechanism that allows the human
species to adapt to dramatic changes in the biotope (self-
assessment/criticism). Regardless of the etiology, depression
can be thought of as part of a mechanism involved in the
process of adapting one’s behavior to life in a rapidly changing,
sometimes hostile world. Therefore, we might expect the
pathophysiological mechanisms underlying depression to be
related to this adaptation process. Below, we will describe how
this common mechanism can be reduced from 5 current theories
on the mechanism of depression.
DESCRIPTION OF OUR MODEL
Behavior can be considered a mechanism where the brain
manages input to create a specific output, which enables
the organism to adapt to changed circumstances within the
biosphere. In humans, input from the senses is primarily
translated within the cerebral cortex into a specific behavioral
output. Sensory information is processed within the posterior
cerebral cortex in a stepwise fashion (Loonen, 2013b). Specific
information is integrated with other sensory information and
transmitted from the primary sensory cortex to the secondary
sensory cortex, from there to the association cortex, and so on.
Within the anterior cerebral cortex, a similar diverging flow
of information occurs, which leads to the activation of specific
brain regions, e.g., the motor cortex. Apart from this stepwise
processing, other fibers connect to more distant regions that run
in parallel. Every neural connection is capable of learning, due
to the characteristics of glutamatergic transmission, which can
increase or decrease the sensitivity of connecting synapses by
inducing long term potentiation (LTP) or long term depression
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(LTD). Therefore, the cortex can “learn” to transmit specific
sensory information to a specific output unit via a “preferred”
cortical tract. Accordingly, the cerebral cortex learns to interpret
sensory information and produce a specific behavioral response.
Although this process is expedient, it can be expected to be
highly sensitive to dysregulation, both in routine functions and in
learning. Therefore, a parallel circuit has evolved, which includes
subcortical structures. All processing units in the cerebral cortex
also send information to the basal ganglia (Heimer, 2003).
The route through the basal ganglia and thalamus leads to
corresponding processing units in the anterior cortex (Loonen
and Ivanova, 2013). This parallel circuit has stimulatory and
inhibitory pathways and its glutamatergic synapses can also
induce LTP and LTD (Figure 1A). Therefore, this parallel
route through the basal ganglia enables the brain to correct
serially transmitted information, when it arrives at the “final”
destination. Moreover, the connection through the basal ganglia
is convergent (Figure 1B; Alexander et al., 1986; Loonen and
Ivanova, 2013; Loonen, 2013b). Hence, the processing units in
the posterior and anterior cortices and their outputs converge
within this subcortical circuit to the same output unit. Again,
the “learning” ability of glutamatergic synapses within this
framework make it possible to process a constantly varying input
and produce very complex, sophisticated output patterns, in a
reproducible, precise fashion.
This organization of connections is well-known as the
extrapyramidal system, which regulates cognition and
movements (Groenewegen, 2003). In our depression model, we
suggest that a similar organization can be distinguished within
the limbic cortex, although here, the structure is more complex
and less modular, due to the ancient origins of these structures
(Loonen and Ivanova, 2015, 2016a; Loonen et al., 2016). To
simplify, we have concentrated on the primary limbic cortex
within the superficial and deep corticoid regions of the amygdala.
These regions are connected with many other archicortical and
mesocortical areas. These corticoid regions can be considered
input areas, and the centromedial (ganglionic or nuclear) region
can be considered the output area of the amygdaloid complex.
The stria terminalis connects the nuclear amygdala to the
diencephalon, and from there, the anterior mesial frontal areas
can be reached (Sewards and Sewards, 2003). However, the
majority of output from the limbic basal ganglia flows to the
brainstem. This connection is probably related to the fact that
cortical motor centers were absent in the earliest vertebrate
ancestors of humans (Loonen and Ivanova, 2015). In lampreys,
movements are directed by diencephalic and brainstem motor
centers (Loonen and Ivanova, 2015). In our opinion, in higher
vertebrates, the nuclear amygdala represents the striatum of our
oldest vertebrate ancestors. Nevertheless, the amygdala affects
the motor output of higher vertebrates, including humans, by
inducing the drive to seek food, warmth, comfort, etcetera, or to
escape from pain, thirst, misery, etcetera (Sewards and Sewards,
2003).
Hence, two types of cortical-subcortical systems may be
distinguished: extrapyramidal and limbic circuits. These systems
have different first step relay stations; the extrapyramidal circuit
includes the caudate nucleus, putamen, and nucleus accumbens
core (NAcbC); the limbic circuit includes the nuclear amygdala,
the connecting extended amygdala, the bed nucleus of the
stria terminalis, and the nucleus accumbens shell (NAcbS).
The extrapyramidal circuit regulates “rational,” cognitively
constructed, skilled behavior, which is often goal-oriented and
includes decision making. The limbic circuit regulates emotional
(instinctive and automatic) behaviors, which are often defensive,
and this regulation includes (attentive) salience. The two systems
influence each other in a reciprocal (yin-and-yang-like) fashion;
moreover, both systems can inhibit or activate, as the situation
demands. It is generally accepted that the prefrontal cortex
(PFC) is in control of selecting the appropriate response (Stuss
and Knight, 2002; Fuster, 2008). The dorsolateral PFC is
particularly important for controlling rational responses, and
the ventromedial PFC controls emotional responses. Within
the ventromedial PFC, the orbitofrontal cortex (OFC) plays a
particularly noteworthy role, because it is essential for regulating
the direction of motivation (Zald and Rauch, 2006).
Behavior can be a reaction to an influence in the environment,
or it can also be generated by the individual. To enable a
reactive or proactive behavior, motivation comes into play
(Rolls, 1999; Stuss and Knight, 2002). Three stages of behavioral
motivation can be distinguished: general motivation, initiative,
and selective precedence-conveying (via inhibition). The OFC
plays a significant role in regulating these processes by delivering
input to the ventral striatum, the anterior cingulate cortex, and
the amygdala.
Although the extrapyramidal and limbic circuits regulate two
different types of behavior (cognitive and intuitive, respectively),
the individual must be highly motivated to express these
conducts. This motivation requires the involvement of two
specific structures: the NAcbC and the NAcbS (Figure 2;
Groenewegen, 2007; Dalley et al., 2008; Loonen and Stahl, 2011).
The NAcbC motivates the individual to show behavior that
may lead to a feeling of reward. The NAcbS motivates the
individual to show behavior that may lead to escape from misery
(Loonen and Ivanova, 2016a). When high stimulation of these
motivations suddenly ceases, the individual experiences feelings
of pleasure (NAcbC) or feelings of happiness (NAcbS). Therefore,
we distinguish between circuits that regulate pleasure and
circuits that regulate happiness (Loonen and Ivanova, 2016a).
In clinical depression, both circuits seem to be dysfunctional.
Low activity in the reward seeking system results in the
inability to experience pleasure (anhedonia), lack of energy, and
indecisiveness. Particularly high activity in the misery-fleeing
system results in continuous worrying, negative expectations,
and dysphoric feelings.
The activities of the NAcbC and NAcbS, in turn, are
regulated by monoaminergic nuclei within the midbrain. These
nuclei transmit signals through dopaminergic (ventral tegmental
area, VTA), adrenergic (norepinephrine, locus coeruleus), and
serotonergic (raphe nuclei) tracts. In addition to their direct
regulation of the NAcbC and/or NAcbS (Loonen and Ivanova,
2016a; Loonen et al., 2016), these monoaminergic nuclei regulate
the activity of other, first relay-station, basal ganglia and
important parts of other areas in the forebrain. Therefore, it
may be concluded that behavioral output is controlled at three
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FIGURE 1 | Cortical-subcortical-processing units. Extrapyramidal units are shown as an example of such cortico-striato-thalamo-cortical processing units. (A)
Direct and indirect pathways lead to activation or inhibition of the anterior cortical endpoint. Abbreviations: D1, medium spiny neurons carrying dopamine D1
(Continued)
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FIGURE 1 | Continued
receptors; D2, medium spiny neurons carrying dopamine D2 receptors; DYN, dynorphin; ENK, enkephalin; GPe, globus pallidus externa; GPi, globus pallidus interna;
SP, substance P; STh, subthalamic nucleus. Red arrows, excitatory; blue arrows, inhibitory. (B) Converging pathways through the basal ganglia correct the serially
connected intracortical connections. Abbreviations: a, sensory input; b, motor output; c, to contralateral cortex; NS, non-specific part of the thalamus; S, specific part
of the thalamus. Red, black, green, blue arrows, undetermined neurochemically.
FIGURE 2 | Stimulation of the core and shell of the nucleus accumbens. Adapted from Dalley et al. (2008). VTA, ventral tegmental area; LC, locus coeruleus.
Red arrows, glutamatergic; blue arrows, GABAergic; gray arrows, dopaminergic; green arrow, adrenergic.
levels within the brain. The highest level is the cerebral cortex
(isocortex, limbic cortex, corticoid amygdala, and hippocampal
complex). The second level is the subcortical forebrain (dorsal
striatum, ventral striatum, and extended amygdala). The third
level of control is the midbrain (monoaminergic regulation
centers).
As part of our depression model, we suggest that a fourth
regulatory system exists, the habenula, which connects the
cerebral cortex and midbrain systems (Figure 3; Loonen and
Ivanova, 2016a; Loonen et al., 2016). Based on the regulation
of appetitive behavior in lampreys, the lateral habenula has an
important regulatory function (Loonen and Ivanova, 2015). In
the lamprey, when a behavior is particularly rewarding, the lateral
habenula promotes this behavior by intensifying stimulation of
the phylogenetic homolog of the VTA.However, when the reward
is smaller than expected or absent, the behavior is discouraged
by inhibiting the VTA-equivalent in the lamprey. A similar
mechanism of reward processing appears to be present in higher
vertebrates (Matsumoto and Hikosaka, 2009; Bromberg-Martin
et al., 2010; Zhao et al., 2015). The medial habenula has been
shown to play a role in misery-fleeing behavior (Robertson
et al., 2014; Viswanath et al., 2014). The habenula is part of
the epithalamus, which also harbors the pineal gland and the
stria medullaris. The habenula’s projections to the midbrain were
well conserved during vertebrate evolution (Hikosaka, 2010;
Viswanath et al., 2014; Loonen et al., 2016). Its input structures
are less certain in higher vertebrates, but they include important
inputs from the septal areas and the amygdalar-hippocampal
complex (Loonen and Ivanova, submitted). The latter inputs
connect the habenula to the cerebral cortex. Moreover, a direct
connection between the PFC and the monoaminergic midbrain
centers affects the activity of the VTA (Loonen et al., 2016).
In conclusion, the extrapyramidal and limbic subcortical
systems regulate cognitive (rational) and instinctive behaviors,
respectively. The intensity of behavior that ultimately leads
to reward is controlled by the cortico-striato-thalamo-cortical
(CSTC) circuit that includes the NAcbC. The intensity of
behavior that ultimately leads to safety is controlled by the CSTC
circuit that includes theNAcbS. On the temporal side of the brain,
the corticoid amygdala determines the appropriateness of flight,
fight, or appetitive responses. Based on attentive salience, the
nuclear amygdala initiates the proper emotional component of
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FIGURE 3 | The organization of the misery-fleeing and reward-seeking regulatory systems. The series of limbic and extrapyramidal basal ganglia that form
converging processing units are separated from each other by the system that contains the nucleus accumbens. These units regulate motivations to exhibit
misery-fleeing and reward-seeking behaviors. The activity of the basal ganglia processing unit is regulated by monoaminergic neurons from the midbrain, which are, in
turn, controlled by the cerebral cortex, through a direct (ventral) and an indirect (dorsal) connection. The dorsal connection includes the habenula and the fasciculus
retroflexus. [Note: the figure is slightly changed in Loonen and Ivanova, (submitted)]. Red arrows, glutamatergic; gray arrows, dopaminergic; purple arrows,
serotonergic; green arrows, adrenergic; black arrows, undetermined neurochemically.
behavior. On the dorsal side of the brain, the caudate nucleus
determines the suitability of the available repertoire of skilled
behaviors; it selects the proper motor response to achieve the
intended goals. The motivation to express these behaviors is
regulated by monoaminergic centers within the midbrain. In
turn, these monoaminergic centers are regulated by the cerebral
cortex and corticoid amygdala through a dorsal connection that
travels through the medial and lateral habenula. In particular,
this latter mechanism is essential for adapting reward-seeking
and misery-fleeing behavior to environmental changes. In the
following overview, it will be shown that the neurobiological
mechanisms involved in this process also appear to be included
in current theories that explain the biological background of
depression.
THEORIES OF DEPRESSION
For many decades, the neurobiology of mood disorders has
been the subject of intensive experimental and clinical research.
Initially, the pharmacological effects of antidepressant agents
were taken as a starting point for developing a theory of
how depressive mood disorders arise. This resulted in the
monoamine theory of depression. Most antidepressant drugs
inhibit pre-synaptic transporters that are responsible for the
reuptake of neurotransmitters from the synaptic cleft (Cooper
et al., 2003; Leonard, 2003; Stahl, 2008). Tricyclic antidepressants
(TCAs) inhibit the reuptake of norepinephrine and serotonin;
in contrast, selective serotonin reuptake inhibitors (SSRIs) only
inhibit serotonin reuptake (Maître et al., 1980). A few substances
also affect the reuptake of dopamine (bupropion), but these
are exceptions to the rule (Stahl, 1998; Feighner, 1999). A
few antidepressants (mirtazapine) block pre-synaptic receptors
and disinhibit the release of norepinephrine (Feighner, 1999).
Psychostimulants also inhibit neurotransmitter reuptake, but
in addition, they promote the release of neurotransmitters
(Riddle et al., 2005). Psychostimulants also affect the release
of dopamine. Classical monoamine oxidase inhibitors (e.g.,
tranylcypromine) decrease mitochondrial metabolism of the
three primary neurotransmitters, serotonin, norepinephrine, and
dopamine (Schildkraut, 1965; Coppen, 1967).
Other pharmacological effects of antidepressant treatments,
in combination with the biochemical abnormalities observed
in patients with depression, have led to the development
of neuroendocrine and neuroimmunological theories of
depressive mood disorders. An extrapolation of these ideas, in
combination with the results of neuroimaging studies, led to the
neuroplasticity theory. This latter theory is based on changes
in neuroplasticity, but it also corresponds to findings from an
electrophysiologically derived model, which is typically used
to explain the increasing susceptibility of developing affective
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episodes in bipolar disorder. An entirely different approach
emerged from the many circadian and seasonal aspects of
depression. However, as we will discuss, this mechanism is
not wholly different from the monoamine hypothesis, and it is
firmly linked to the neuroendocrine and neuroimmunological
theories. Therefore, five different theories can be distinguished:
the monoamine hypothesis, the biorhythm hypothesis, the
neuroendocrine hypothesis, the neuro-immune hypothesis,
and the kindling (neurogenesis/neuroplasticity) hypothesis
(Loonen, 2013a). We will briefly describe the backgrounds of
these theories, with an eye to how they relate to the effects of
neuroplastic changes, according to our depression model.
THE MONOAMINE HYPOTHESIS
The oldest and most important theory on the pathogenesis of
depression was developed in the 1960s and 1970s. That theory
holds that depression is caused by a dysfunction in adrenergic
or serotonergic neurotransmission (Van Praag, 1982; Baker and
Dewhurst, 1985). Two observations formed the basis of this
theory. First, it was observed that reserpine, an antihypertensive
and antipsychotic drug, depleted monoamine neurotransmitters
in the brain, and that this drug caused major depression in
a significant proportion of patients that used it (Freis, 1954).
The second observation was that, at that time, all known
antidepressant drugs modified the levels of norepinephrine
and serotonin (Schildkraut, 1965; Coppen, 1967). Later studies
showed that cerebral spinal fluid levels of monoamines and
their metabolites were quite different in patients with depression
compared to individuals without depression (Schildkraut, 1965;
Van Praag and Korf, 1971; Riddle et al., 2005). However, the main
problem with this theory was that, although these drug-related
changes occurred immediately after the initiation of treatment
(Maître et al., 1980), the therapeutic effects occurred with a
lag time of about 2 weeks. With the advent of the receptor
binding technique, this lag time is currently thought to result
from the fact that neurotransmitter receptor levels adapt slowly to
pharmacologically-induced changes (Baker andDewhurst, 1985).
Chronic treatment with antidepressants were found to induce
a decrease in the sensitivity of serotonin type-1A (5-HT1A)
receptors in the hippocampus (Sibug et al., 1998; Subhash et al.,
2000) and an increase in the sensitivity of β-adrenoceptors in the
cerebral cortex (Sugrue, 1983).
The monoamine hypothesis arose from the observation
that brain function depended on the existence of specific
neurotransmitter systems (Nieuwenhuys, 1985; Nieuwenhuys
et al., 2008). Here, we must distinguish between major and
minor neurotransmitter systems (Loonen, 2013a,b). The vast
majority of central nervous system (CNS) neurons secrete
either glutamate (30%) or γ-aminobutyric acid (GABA; 50%)
as neurotransmitters. These major transmitter systems are
responsible for the evaluation and memorization of all sensory
input. Moreover, these systems initiate, coordinate, and control
all motor output from the brain. However, monoaminergic
neurons, which secrete dopamine, norepinephrine, serotonin,
or histamine as neurotransmitters, are far more important
for neuropsychopharmacologists, even though these neurons
comprise less than 2% of CNS neurons (Loonen, 2013a).
This focus is probably related to the low acute toxicity of
centrally-acting drugs, which act by interfering with monoamine
receptors. For example, in the 1980s, patients with psychoses
were treated with haloperidol, pimozide, or fluphenazine at
daily dosages that corresponded to approximately 10,000
chlorpromazine equivalents (Andreasen et al., 2010), as part of a
rapid neuroleptisation procedure (AJML, personal observation).
Actually, some patients went swimming in spite of taking
these extreme dosages, which must have blocked all available
CNS dopamine receptors and may have also blocked serotonin,
histamine, and norepinephrine transmission. These drugs were
relatively safe, because they targeted minor systems, which
are not directly responsible for evaluation and control, but
smoothly regulate the activity levels of major neurotransmitter
systems. Due to this low CNS toxicity, drug formulations
that displayed unreliable pharmacokinetics or a non-specific
pharmacodynamic profile could be used safely in treating
patients with mental illnesses, which was certainly not possible
with drugs that interfered to a large extent with glutamatergic
neurotransmission.
The adrenergic and serotonergic systems have been
intensively studied to explain the antidepressant effect of
currently available pharmacotherapeutics. However, within the
context of our depression model, the dopaminergic system is also
critically important. As stated above, almost all antidepressants
increase the concentration of norepinephrine and/or serotonin
within the synaptic cleft. However, this is an acute effect,
and it does not explain the lag time between the initiation of
drug treatment and the start of clinical improvement. Shortly
after the discovery of neurotransmitter binding sites, about
four decades ago, it was found that chronic treatment with
antidepressant drugs resulted in downregulation of β-adrenergic
and 5-HT2 receptors (Sugrue, 1983). Since then, it has become
clear that downregulation of postsynaptic β-adrenoceptors
is a consistent and robust effect of chronic treatment with
most antidepressants, and this effect is accelerated by co-
treatment with SSRIs (Anand and Charney, 2000). Moreover, the
serotonergic system, particularly the 5-HT2C receptor, seems to
be involved in mediating antidepressant activity. The progressive
downregulation of these receptors parallels the gradual onset of
clinical effects observed with SSRIs (Millan, 2005). Hence, the
acute effects of antidepressants are not believed to mediate their
clinical activity; instead, clinical activity is due to the decreased
sensitivities of β-adrenergic and 5-HT2C receptors, which are
consequences of the acute effects.
The Adrenergic, Dopaminergic, and
Serotonergic Systems
Norepinephrine was the first neurotransmitter thought to be
involved in the mechanism of action of antidepressants. All cell
bodies that produce this minor neurotransmitter are situated in
the brain stem; about half are in the locus coeruleus complex,
and the remainder are in a set of nuclei (A1, A2, A5, A7)
of the autonomic nervous system (Figure 4A) (Nieuwenhuys,
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1985; Nieuwenhuys et al., 2008; Loonen, 2013a,b). Fibers
of these adrenergic neurons project to the diencephalon.
The hypothalamus is primarily innervated by the group of
“autonomic” brainstem nuclei (Nieuwenhuys, 1985). These
projections are thought to be involved in, for example, the neuro-
endocrine response (al-Damluji, 1993). Another set of adrenergic
fibers runs from the brainstem, through the medial forebrain
bundle, to more rostral parts of the forebrain (Figure 4A).
The hippocampal complex, amygdala, and cerebral cortex are
primarily innervated by adrenergic fibers that originate from the
locus coeruleus (Nieuwenhuys, 1985). These fibers are believed to
play important roles in arousal and impairments in PFC function
during stress (Ramos and Arnsten, 2007).
In the 1970s, the involvement of the serotonergic system
in the pathogenesis of depression was postulated by, among
others, Van Praag (1982). The cell bodies of serotonergic neurons
are located in the brain stem, and because they are found
in the vicinity of the midline (the raphes), these nuclei are
termed the upper and lower raphe nuclei (Figure 4B). The
distribution of serotonergic fibers is somewhat more extensive
than that of adrenergic fibers (Nieuwenhuys, 1985). Serotonergic
fibers project to the spinal cord, several brain stem nuclei, the
cerebellum, and the diencephalon (hypothalamus). Forebrain
structures innervated by these fibers include the basal ganglia,
the hippocampus, and the cerebral cortex (Nieuwenhuys, 1985).
Seven types of serotonin receptors have been found, and all
but one (5-HT3) are G-protein coupled receptors (Aghajanian
and Sanders-Bush, 2002; Hoyer et al., 2002; Cooper et al., 2003;
Leonard, 2003; Hannon and Hoyer, 2008; Loonen, 2013b). Most
of these receptors are divided into several subtypes. Subtypes
5-HT1A, 5-HT2A, and 5-HT2C receptors have been most
extensively studied for their role in depression. Stimulation of 5-
HT1A receptors results in an increased influx of K+ ions and
membrane hyperpolarization, which inhibits neurotransmission.
Stimulation of 5-HT2A or 5-HT2C receptors has the opposite
effect.
The dopaminergic system is thought to be primarily involved
in psychosis and mania. However, in both mood disorders
and schizophrenia, the dopaminergic system may also play a
role in the development of depressive symptoms (particularly
anhedonia) (Figure 4C; Loonen and Ivanova, 2016a). The
midbrain (mesencephalon) contains three areas, A8, A9, and
A10 (Nieuwenhuys, 1985). The latter two correspond to the
substantia nigra pars compacta and the VTA. From there,
dopaminergic fibers project to the dorsal and ventral striata,
to the PFC, and to the mesial part of the temporal lobe.
Previously, nigrostriatal (dorsal striatum), mesolimbic (ventral
striatum), and mesocortical (cerebral cortex) projections were
differentiated, but currently, these divisions are no longer
distinguished (Nieuwenhuys, 1985).
Monoamines and Antidepressant Activity
As described above, the adrenergic system influences the
hypothalamus and the PFC. Depression is accompanied by
a reduction in norepinephrine production and altered α2-
adrenoceptor sensitivity, as reflected by the growth hormone
response to clonidine (Anand and Charney, 2000). Because
the hypothalamus is a controller of this partly endocrine
response (Loonen and Ivanova, 2016a), it can be speculated
that this feature of depression reflects a change in the ability
of the hypothalamus to initiate a proper flight response.
This deficiency may lead to the stimulation of compensatory
mechanisms and result in hyperactivation of the misery-
fleeing system. β-Adrenoceptors are predominantly located in
the cerebral cortex, nucleus accumbens, and striatum (Pazos
et al., 1985; Reznikoff et al., 1986; Arango et al., 1990; Joyce
et al., 1992). By downregulating β-adrenoceptors in the NAcbS,
antidepressants would dampen the misery-fleeing response
by reducing its activity (Loonen and Ivanova, 2015, 2016a).
However, modulating the effects of adrenoceptor stimulation
within the PFC may also contribute to the antidepressant
effects. To our knowledge, the precise role of β-adrenoceptors
within the nucleus accumbens has not been extensively studied.
However, serotonin is known to inhibit adrenergic function
in the locus coeruleus complex (Stahl, 2009; Monti, 2011).
Moreover, serotonin inhibits dopaminergic neurotransmission,
both by inhibiting dopaminergic midbrain nuclei and by
inhibiting dopamine release from terminal synapses, for example,
in the PFC (Bonhomme and Esposito, 1998; Stahl, 2009;
Morita and Nakayama, 2011; Loonen and Ivanova, 2016b).
These inhibitory effects are mediated through excitatory 5-
HT2A/2C receptors on fast-spiking GABAergic interneurons.
However, there are important differences between 5-HT2A and
5HT2C receptors in their degrees of involvement in mediating
serotonergic effects in the ventral and dorsal striata (Loonen and
Ivanova, 2016b). It should be noted that SSRIs may augment
parkinsonism in vulnerable patients (Leo, 1996; Gerber and
Lynd, 1998). These effects are probably mediated by stimulating
5-HT2A/2C receptors, and they are counter-productive in
alleviating depression. However, drugs like mirtazapine and
trazodone, which are known to block these receptors, may exert
antidepressant activity through the same mechanism (Millan
et al., 2000; Stahl, 2009). Dopamine has an important stimulatory
influence in the PFC (Arnsten, 2011). This may alleviate the
lack of initiative (dorsolateral PFC) and activate circuits that
motivate reward-seeking behaviors (mesial PFC and nucleus
accumbens). However, dopamine is probably only important in a
subset of patients, based on the limited efficacy of dopaminergic
drugs (e.g., classical monoamine oxidase inhibitors) in “normal”
depression and their high efficacy in depressions refractory to
TCAs and SSRIs (Stahl and Felker, 2008).
Apart from their direct influences on the hypothalamus
and PFC, serotonergic projections also affect temporal lobe
structures, like the amygdaloid complex and hippocampus
(Nieuwenhuys, 1985; Graeff et al., 1996; Berumen et al.,
2012). In our model, an important overlap exists between the
antidepressant and anti-anxiety effects of serotonergic drugs.
Both effects are reported to be related to relief from a chronic
stress-related state. Serotonergic fibers that originate in the
dorsal and medial raphe nuclei regulate amygdalar activity by
stimulating the 5-HT2 receptor family. However, the precise
role of the 5-HT2A vs. the 5-HT2C receptor is not known
(Bombardi, 2014). Moreover, the role of the 5-HT2B receptor
has rarely been studied. The amygdala plays an important role in
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FIGURE 4 | Three monoaminergic neurotransmitter systems. Adrenergic (A), serotonergic (B), and dopaminergic (C) neuropathways. Cell bodies are in the
nuclei (red-filled shapes) positioned within the brainstem. Nerve fibers (red lines) terminate in the dorsal and ventral striata, amygdala, and frontotemporal cortex
(Nieuwenhuys, 1985; Loonen, 2013b).
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initiating the emotional response by activating the hypothalamus
to execute, for example, anxiety/fear schemes (Aggleton, 2000;
Inoue et al., 2011). The amygdala receives input from various
brain structures (also unidentified sensory information), and
it can react very quickly to this information in case of a
possible threat. This rapid response is partly due to response
conditioning (Pare and Duvarci, 2012; Maren et al., 2013). This
input is transmitted from the sensory association cortex, the
limbic cortex, and the parahippocampal region (Sinclair et al.,
2009). The antidepressant effects of SSRIs may be related to
the downregulation of 5-HT2C receptors. At the onset of SSRI
treatment, indirect activation of 5-HT2C receptors participates
in anxiogenic effects and the inhibition of sleep, sexual behavior,
and appetite (Millan, 2005). This condition is known as the
“jitteriness/anxiety syndrome” (Sinclair et al., 2009). Conversely,
progressive downregulation of 5-HT2C receptors parallels the
gradual onset of clinical SSRI efficacy (Millan, 2005). This
downregulation may result in decreased sensitivity to fear-
inducing or stress-inducing input and decreased activity in the
limbic circuit, which may explain both the antidepressant and
anxiolytic effects of SSRIs. We believe that these effects are
mediated within the amygdaloid complex (Loonen and Ivanova,
2016a).
The hippocampal complex plays an important role as a
controller of declarative memory formation (Eichenbaum, 2006;
Cutsuridis and Wennekers, 2009). Within the hippocampal
region, sensory information is identified as either something
that occurred previously or something new and unexpected
(Loonen, 2013b). Therefore, the hippocampal complex may have
an important influence on the amygdala. The initiation of an
emotional response is either facilitated with a warning (e.g.,
potential harmful situation) or inhibited with an assurance (e.g.,
innocent object, no threat). Thus, when a potentially harmful
object is identified, the emotional response may be inhibited,
then followed by facilitation of a cognitive defense reaction,
when the hippocampal complex sends outputs to different parts
of the PFC (Warburton and Brown, 2010; Euston et al., 2012).
Serotonin has complex effects on hippocampal function. A
chronic dysfunction of the hippocampus may result in a chronic
state of hyperarousal and fear. Serotonin has two receptor effects
that prevent hippocampal dysfunction: it directly stimulates 5-
HT1A receptors (Ogren et al., 2008) and it modifies the effects
of glucocorticoid receptors (GRs) (Erdeljan et al., 2001; Laplante
et al., 2002). Stress and glucocorticoids are known to induce
hypoplasia in the hippocampus, and the SSRI fluoxetine has been
shown to protect hippocampal neurons against this influence
(Czéh et al., 2007; Nagano et al., 2012). It is possible that
both receptor effects are strongly interrelated. However, other
biological responses may also result from the stimulation of 5-
HT1A receptors (Ogren et al., 2008; Savitz et al., 2009). Very
little is known about a possible influence of 5-HT2B receptors.
Some studies suggest that 5-HT2B receptors may play a role
in embryonic development (e.g., of the enteric nervous system)
(Nebigil et al., 2001), and at least part of their effects may include
modulating the activity of astrocytes (Hertz et al., 2015). In this
context, the experiments of Diaz et al. (2012) are interesting.
They found that genetic or pharmacological inactivation of
5-HT2B receptors could abolish some long-term behavioral and
neurogenic SSRI effects and greatly attenuate the SSRI-induced
increase in hippocampal extracellular serotonin concentrations.
Conversely, direct agonists of 5-HT2B receptors mimicked these
SSRI effects in the absence of SSRIs (Diaz et al., 2012). Hence,
stimulation of 5-HT2B receptors may play a role in mediating
the neurogenic effects of SSRIs. Serotonin is believed to promote
adequate functions, or to suppress inadequate functions of the
hippocampal complex. Either effect would result in inhibiting
the amygdala, which would abolish an inadequate emotional
response. As a result, the cognitive response would be allowed
to take over. This would result in relieving an emotional disorder,
whether amood disorder or an anxiety disorder. This mechanism
might explain the additive effects of cognitive behavioral therapy
in combination with SSRIs in treating refractory depression
(Wiles et al., 2013). Thus, SSRIs enhance the ability of the PFC to
adopt cognitive schemes that limit stressful, depressive responses.
Based on the foregoing observations, it can be concluded that
norepinephrine, serotonin, and dopamine may play important
roles in the genesis of depressive disorders. The role of dopamine
is restricted to a specific subset of depressive reactions, including
TCA/SSRI refractory depression, depression in schizophrenia
(caused by dysfunction of the PFC), depression in Parkinson’s
and Alzheimer’s Diseases, and antipsychotic drug-induced
depression. We propose that norepinephrine primarily exerts
effects in the hypothalamus, PFC, and striatum (including the
dorsal striatum and NAcbS), and that serotonin primarily exerts
effects in the hippocampal complex/amygdala. In both cases, the
effects increase the likelihood that an inappropriate response is
suppressed and an appropriate response takes over. This explains
the time needed for an actual change to occur. Thus, it is the basis
for the lag in treatment effects.
BIORHYTHM HYPOTHESIS
Several aspects of the symptomatology of depression indicate
a malfunction in the biological clock (Wirz-Justice, 2006;
McCarthy and Welsh, 2012). Depressive disorders are well
known to be accompanied by sleep disturbances (Fleming, 1989;
Thase, 1998; Tsuno et al., 2005; Srinivasan et al., 2009; Aizawa
et al., 2013). In patients with a depressive disorder, the time
period between the moment they fall asleep and the moment
of detecting the first rapid eye movement (REM) episode,
is remarkably shorter than in individuals without depression.
In some individuals with depression, REM sleep occurs
instantaneously. This phenomenon results in a remarkable
distortion of the sleep architecture; i.e., the sequence of sleep
stages during the night. Moreover, patients with depression
experience interrupted sleep and late night insomnia. Apart from
these sleep disturbances, other biorhythm disorders are evident
in depression (Thase, 1998; Bunney and Bunney, 2000). In some
patients, mood and other symptoms show typical fluctuations
in severity over the day (Tölle, 1991). In the morning, they
typically feel worse, and during the course of the day, things tend
to improve slightly. Also other biorhythms become irregular,
such as body temperature and the cortisol rhythm (Bunney and
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Bunney, 2000). Moreover, in some patients, depressive episodes
show a typical seasonal pattern (Rosenthal et al., 1987; Melrose,
2015).
Different sleep disorders can be illustrated by comparing
hypnograms between patients without or with depression,
before and after treatment with electroconvulsive therapy (ECT)
(Haffmans et al., 2006). The hypnogram of a patient in depression
is entirely different from a normal hypnogram. The sleep phases
are irregularly distributed, and the sequence of sleep phases is
abnormal. After a patient recovers from depression, a normal
hypnogram is observed (Haffmans et al., 2006; Loonen, 2013a).
The described biorhythms depend on the function of several
genes that regulate the endogenous biological clock (Bunney
and Bunney, 2000; Wirz-Justice, 2009; McCarthy and Welsh,
2012). A circadian pacemaker in the brain comprises a group of
approximately 10,000 neurons in the nucleus suprachiasmaticus
(SCN) of the anterior hypothalamus. This pacemaker conducts,
drives, and synchronizes all 24-h rhythms in the body (Wirz-
Justice, 2009; McCarthy and Welsh, 2012). When isolated in
culture, SCN neurons “tick” at an endogenous frequency, driven
by constitutive clock genes (Wirz-Justice, 2009). Both the SCN
and individual SCN cells have a circadian period, which is
typically somewhat longer than 24 h in humans (Pagani et al.,
2010). Thus, to synchronize to the 24-h day-night cycle, the
SCN requires daily entrainment signals, so-called “Zeitgebers.”
Daylight and melatonin play important roles in the entraining
process. The interaction between daylight, melatonin, and the
circadian rhythm is highly complex (Wirz-Justice, 2009; Bunney
and Bunney, 2012); here, we will represent the entrainment
process with a model that is highly simplified (and not entirely
correct) (Loonen, 2013b). According to this model, the biological
clock of the SCN is reset by full exposure to daylight, when the
eyes are opened and daytime activity starts. The SCN is directly
connected to the retina by fibers that deviate from the optic
tract (Figure 5). Therefore, this mechanism also functions in
cortical blindness, but not in retinal blindness. The sensitivity to
entrainment by daylight is thought to be enhanced by melatonin
in both the retina and the SCN. Melatonin is a hormone secreted
by the pineal gland during sleep, provided that the sleep period
matches the night phase of the circadian rhythm. Melatonin
secretion is stimulated by fibers in a branch of the sympathetic
nervous system that projects from the superior cervical ganglion
to the pineal gland and by fibers that originate in the SCN.
Melatonin binds to specific receptors in the SCN (Mel-1a) and in
the retina (Mel-1b). These two locations explain why treatment
with an evening dose of melatonin has therapeutic effects on
biorhythms in patients with dysfunctional retinas (e.g., retinal
blindness) (Skene and Arendt, 2007). Upon awakening, the
presence of melatonin increases SCN entrainment by daylight.
However, studies on melatonin and sleep have reported many
contradictory findings.
The biorhythm hypothesis of depression postulates that
depressive symptoms are caused by a dysfunction in the SCN that
affects the generation of a correct circadian rhythm (Wirz-Justice,
2006; Bunney and Bunney, 2012; McCarthy and Welsh, 2012).
One hypothesis says that, in depression, there is a mismatch
between the biological rhythm and the true natural rhythm.
When the biological rhythm is shorter than 24 h, the mismatch
may cause a false start. It is possible that a false start might
cause serious problems. However, contradictory results were
reported from studies that aimed to establish a phase-advance
in the overall 24-h pattern of body temperature in patients
with depression (Bunney and Bunney, 2012). Another hypothesis
holds that a disorder in entrainment causes depression, at least
in some patients. This disorder may arise when daylight is
insufficient to produce a “Zeitgeber.” In turn, this insufficiency
may be related to insufficient retinal stimulation by daylight or
insufficient sensitivity of the SCN, or both. A subpopulation
of patients with depression experienced therapeutic effects with
exposure to bright light, in addition to treatment with an evening
dose of melatonin (Terman and Terman, 2005; Pail et al., 2011).
However, many patients with depression do not respond to bright
light treatment. Therefore, this mechanism is not likely to be
the primary defect, and depression may not be comparable to
a sort of exaggerated hibernation state in humans. However,
the therapeutic results could suggest that, in a subpopulation of
patients, this mechanism may play a role by inducing neuro-
endocrine disturbances that are related to the pathogenesis of
depression.
In addition to the SCN, the habenula may also play an
important role in depression. The habenula has reciprocal
connections with the pineal gland, and these structures have
evolved in close association (Hikosaka, 2010; Loonen and
Ivanova, 2015). The habenula plays a prominent role in
sleep, particularly by regulating REM sleep (Hikosaka, 2010).
Moreover, the habenula has important functions in reward-
based decision making, avoidance of punishment, and behavioral
responses to stress (Hikosaka, 2010). In some species, these
processes may be closely linked to animal migration. The lateral
habenula receives inputs from both the SCN and melanopsin
retinal ganglion cells, which provide light entrainment signals to
the circadian system (Benarroch, 2015). It is very possible that
changes in the daily dark-light rhythm induce some animals to
start migrating to improve the reward they perceive from daily
living circumstances. In some animals, the habenula controls
behavior that is induced by detecting changes in electric or
magnetic fields, and these fields may play an important role in
navigation (Hikosaka, 2010). The interaction between the SCN
and the habenula may link the biorhythm hypothesis directly
to our framework of the control of reward-seeking and misery-
fleeing activities.
NEURO-ENDOCRINE HYPOTHESIS
The neuro-endocrine hypothesis holds that depressive disorders
result from dysregulation of the endocrine system. At least three
endocrine subsystems have been postulated to play important
roles in the pathogenesis of depressive disorders. One endocrine
subsystem includes the thyroid gland and another subsystem
includes the endocrine gonads. Each of these subsystems is
known to function improperly in a variety of mood disturbances
(Esposito et al., 1997; Tichomirowa et al., 2005; Studd and Nappi,
2012). Although relevant, discussing these subsystems can be
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FIGURE 5 | The network that regulates circadian rhythms. Retinal fibers are directly connected to the suprachiasmatic nucleus and thalamus. The
suprachiasmatic nucleus is connected to the paraventricular nucleus, which influences endocrine and sympathetic activity. Sympathetic fibers from the superior
cervical ganglion regulate melatonin secretion from the epiphysis. 1, retina; 2, suprachiasmatic nucleus; 3, paraventricular nucleus; 4, thalamus; 5, pineal gland; 6,
raphe nuclei; 7, superior cervical ganglion. Red, orange, and blue arrows, undetermined neurochemically.
considered a separate subject; therefore, we will not deal with
them here in further detail.
In this review, we will concentrate on a third subsystem,
the hypothalamic–pituitary–adrenal (HPA) axis (Fava, 1994;
Merola et al., 1994; Stokes, 1995). Several HPA abnormalities are
observed in mood disorders; however, they are not consistently
observed, and they seem to be variable among different
subgroups of patients with depression. It is evident that cortisol
plays a multifaceted role. With depression, diurnal cortisol
rhythms are disturbed, patients are resistant to the feedback
action of exogenous glucocorticoids (e.g., dexamethasone), and
basal cortisol levels may be elevated (Herbert, 2013). In addition,
in several types of depression, patients do not respond to the
administration of corticotrophin releasing hormone (CRH) with
the expected increase in cortisol levels. These findings indicate
that impaired corticosteroid receptor function may be the key
mechanism in the pathogenesis of depression. This impairment
results in dysfunctional stress hormone regulation. Specific tests
were developed to detect compromised corticosteroid receptor
function. The most sensitive test combined the administration of
dexamethasone and CRH (Ising et al., 2005). These tests showed
that the HPA axis exhibited hyperactivity and low sensitivity to
feedback inhibition in patients with MDD. These changes are
currently believed to be orchestrated by CRH.
Studies have demonstrated that, in depression, abnormal
functions could be detected at the level of the hypothalamus
(Raadsheer et al., 1994, 1995). CRH is secreted from
hypothalamic paraventricular cells, and it stimulates the
pituitary gland to produce ACTH; ACTH stimulates the cortex
of the suprarenal glands to secrete cortisol into the general
circulation. Finally, circulating cortisol inhibits CRH secretion
from the hypothalamus and ACTH secretion from the pituitary
gland, which represents an inhibitory feedback loop. This
feedback loop appears to be disrupted in depression (Bao et al.,
2008). In depression, the hypothalamic paraventricular cells
display hyperplasia, and thus, they secrete elevated levels of CRH
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into the primary portal circulation of the pituitary gland. In
response, the pituitary gland produces elevated ACTH, which
then stimulates the adrenal glands. However, elevated cortisol
levels do not appear to correct the levels of CRH and ACTH.
CRH is an important component of the complex emotional
response initiated and controlled by the hypothalamus (Loonen
and Ivanova, 2016a). In addition, CRH is an intracerebral
neurotransmitter and/or neuromodulator, which was shown to
cause an acute increase in the firing rate in the locus coeruleus
(Anand and Charney, 2000). In turn, the high firing rate could
result in stimulating the CSTC circuit that includes the NAcbS,
which would increase the motivation to flee from misery-
inducing stress.
Cortisol is secreted from the adrenal glands in hourly
pulses. The largest pulse amplitude occurs at the beginning
of the circadian activity period (Joëls et al., 2012; Gibbison
et al., 2013). Cortisol can penetrate into the brain, where it
has multiple effects, depending on the concentration (Joëls,
2006; Joëls et al., 2006, 2012). At low concentrations, cortisol
induces recovery and repair, and it prepares the cerebrum for
an adequate, rapid response to stressful situations, through
nuclear (genomic) mineralocorticoid receptors (MRs). At high
levels, cortisol modifies and optimizes the stress response. High
cortisol normalizes brain activity some hours after exposure
to a stressful event and promotes consolidation of the event
for future use, through nuclear glucocorticoid receptors (GRs).
However, high cortisol also directly activates the hippocampus
and other limbic structures, which induces them to participate
actively in the stress response, through membrane-associated
(nongenomic) MRs (Joëls et al., 2006, 2012). Thus, high cortisol
levels facilitate the emotional response and inhibit the cognitive
response to stress. In addition, high cortisol levels protect CNS
nerve cells against potential damage due to uncontrolled, heavy
activity.
As mentioned, cortisol affects the hippocampus and other
limbic areas (Joëls et al., 2012). These regions express two
types of cortisol receptors; MRs and GRs. However, the
mineralocorticoid, aldosterone, penetrates poorly into the brain,
and its blood concentration is roughly 100-fold lower than
cortisol concentrations (Joëls et al., 2012). Therefore, aldosterone
probably rarely binds to cerebral MRs, and it is not likely
to play a major role in the brain. In contrast, cortisol, a
glucocorticoid, binds to both MRs and GRs, which are ligand-
driven transcription factors that regulate genomic expression
in the cell nucleus. Thus, MRs and GRs are called nuclear or
genomic receptors (Joëls et al., 2012). MRs have a high affinity for
cortisol, and they can bind to cortisol even at low concentrations;
i.e., during the nadir/interpulse intervals of the cortisol secretion
curve. Activation of MRs causes tonic inhibition in nerve cells,
which maintains cell integrity and stability. Therefore, MR
activation proactively controls the stress response; the cell is
in a state of readiness. Apart from nuclear MRs, there are
also membrane-bound MRs, with far lower affinity for cortisol
(Joëls et al., 2006). Membrane MRs mediate rapid alterations in
hippocampal excitability at the beginning of the stress response
(Joëls et al., 2012).
GR receptors have low affinity for cortisol (Joëls et al., 2012).
GR receptors are only activated when cortisol levels are high. This
activation is not specific, because MRs are maximally activated
under these conditions. Activation of the GR is particularly
useful for ending the stress response. Thus, GR activation
reactively controls the stress response. In addition, membrane-
associated (nongenomic) GRs are also activated. Within the
hypothalamus and amygdala, activation of membrane GRs
suppresses neuronal activity (Joëls et al., 2012). Within the
hypothalamic paraventricular nucleus, this effect is probably
related to a rapid feedback mechanism.
In patients with a depressive disorder, the function of this
mechanism is altered (Lucassen et al., 2006; Joëls, 2011). It has
been postulated that sustained hyperactivity in the HPA-axis
and a MR/GR imbalance, precipitated by (early) life stress, may
generate a phenotype that is vulnerable to depression (De Kloet
et al., 2005). Thus, when the functions of MRs and GRs are
imbalanced in the hippocampus, hypoplasia may occur, and the
consequence is hippocampal dysfunction (De Kloet et al., 2005;
Lucassen et al., 2006). When the hippocampus fails to form
declarative memories and cannot identify objects and events, the
emotional fear response will dominate the picture.
A few experimental findings have indicated that the
antidepressant effects of drugs, particularly SSRIs, are related to
the effects of cortisol on the hippocampus. Stimulating 5-HT1A
receptors protected the hippocampus against cortisol-induced
dysfunction and cortisol-induced hypoplasia (McAllister-
Williams et al., 1998; Wang et al., 2009). Also, chronic
SSRI-mediated stimulation of 5-HT1A receptors appeared to
repair the MR/GR imbalance (Lai et al., 2003; Zhou et al., 2014).
This repair could restore the ability of sensory information to
inhibit the amygdala appropriately, which removed the apparent
danger perceived, and placed the individual at ease.
The foregoing descriptions should be considered an
oversimplification, because the hippocampus is not a
homogeneous brain area. A converging body of evidence
has indicated that the hippocampus is functionally dissociated
along its septo-temporal axis; the dorsal section is more involved
in learning/memory and spatial navigation, and the ventral
region is more linked to emotional behavior and regulation
of the neuroendocrine stress axis (Tanti and Belzung, 2013).
Animal models of depression exhibit effects restricted to the
ventral hippocampus; in contrast, SSRIs act more uniformly on
dorsal and ventral adult neurogenesis (Tanti and Belzung, 2013).
Moreover, cortisol also directly affects the corticoid amygdala
and the medial PFC (Joëls et al., 2012). These regions may also
be targeted by serotonergic drugs.
It should be emphasized that hypovolemia of the
hippocampus is not necessarily related to the same mechanism
involved in the dysfunction associated with depressive disorder.
In an excellent review article, Czéh and Lucassen (2007)
argued that hippocampal shrinkage was probably not due to
either a decline in neuronal development in the dentate gyrus
or an increase in neuronal cell death. In fact, hippocampal
hypovolemia may primarily result from fluid loss, due to a
shift of fluid between the extracellular fluid compartment
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and cerebrospinal fluid or blood. This problem remains to be
elucidated.
Despite the fact that neurogenesis and morphological changes
(e.g., dendritic shrinkage) make small contributions to changes
in hippocampal volume, these factors may be important for
function. Most studies have been conducted in animal models,
particularly rodents, where morphological changes are probably
far more elaborate than in primates, including humans. However,
despite these limitations, the neuroplastic changes observed most
likely reflected important functional changes (Fuchs et al., 2006;
Masi and Brovedani, 2011; Suri and Vaidya, 2013).
This brings us back to the role of serotonin. We previously
hypothesized that the fear-flight response was initiated by
the amygdala and controlled by the hypothalamus (Loonen
and Ivanova, 2016a). The amygdala sends a signal to the
hypothalamus to start or increase an emotional fear/flight
reaction, in response to sensory information received in the
corticoid part of this complex. This process is facilitated or
inhibited by information stored in the hippocampus through the
hippocampal identification and memorization process (episodic
memory). After identification, the hippocampus sends an
inhibitory signal to the amygdala and medial habenula and a
stimulatory signal to the PFC, to ensure an adequate, cognitively
planned response.
In addition to this mechanism, chronic stress induces direct
neuroplastic changes in the medial PFC and in the amygdala
(Fuchs et al., 2006). We will return to this phenomenon later.
In conclusion, many considerations support the notion that
depression is related to inadequate biological stress management.
This situation may result from an imbalance between GR and
MR functions, particularly (but not exclusively) within the
hippocampus. This imbalance may be reflected by neuroplastic
alterations in hippocampal neurons. We believe that these
alterations correlate with inappropriate interactions between
the hippocampus and the amygdala, the hippocampus and the
medial habenula, and possibly, also between the hippocampus
and the PFC. This could result in inadequate selection
of a depressive emotional response, which corresponds to
hypermotivation to escape from exaggerated misery.
NEURO-IMMUNE HYPOTHESIS
Before we discuss the neuro-immune hypothesis for the
pathogenesis of depressive disorders, we must describe
the influence of neurotrophic factors (Friedman, 2012). As
mentioned above, cortisol has profound neuroplastic activity.
Stimulation of corticoid receptors in the hippocampus resulted
in neuroplastic alterations. This type of activity is exhibited
by many neurotrophic factors, including some cytokines that
are produced by immuno-competent cells, both inside and
outside the brain (Licinio and Wong, 1997; Dantzer, 2007;
Khairova et al., 2009; Capuron and Miller, 2011). In addition, the
functions of the HPA axis and the immune system are intricately
interconnected. Both systems can be considered essential
constituents of the biological defense mechanism against sources
of misery, like attacks from other living organisms (e.g., germs
or predators). Also, both systems consist of mutually interacting
biochemical and behavioral components. During the last two
decades, it has also become evident that the CNS contains
its own immune system, that this immune system is actively
involved in stress reactions, and that an important interaction
exists between the CNS and peripheral immune systems, on
one hand, and between both immune systems and other CNS
regulatory systems, on the other hand (Lampron et al., 2013).
These interactions are separate from the role of microglia, which
probably also regulate CNS functions in a non-inflammatory
manner (Graeber, 2010; Kettenmann et al., 2013).
Neurotrophic or neural growth factors have profound actions
on nerve cell functions (Friedman, 2012). They enhance or limit
axon and dendrite sprouting and the formation of new neuronal
branches and projections. They bind to specific receptors
expressed on nerve and glia cells. Similar to peripheral neurons,
new nerve cell branches in the CNS are believed to find their
way to specific target cells by following chemotactic neurotrophic
factors produced by specific neuroglia cells that function as
“guidance” cells. Moreover, when a nerve cell makes contact with
a neuron, specific neurotrophic factors modify the contact point
to form a regular synapse. Also, synaptic activities are regulated
by neurotrophic factors. In contrast, other neurotrophic factors
inhibit specific synapses, induce regression of neuronal contacts
and branches, and even induce apoptosis. Well known examples
of neurotrophic factors include nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF), in addition to several
neurotrophic cytokines (Friedman, 2012). Thus, cytokines, which
are primarily associated with immune system function, comprise
an important category of neurotrophic factors.
Cytokines are regulatory proteins that can act as autocrine,
paracrine, or endocrine (humoral) factors (Dantzer, 2007) by
binding to specific, high affinity, cell surface receptors. They
are produced by different immune-competent cells and have
pleiotropic effects (multiple actions and multiple target cells),
including important effects in the CNS (Licinio and Wong,
1997; Miller et al., 1999). When immune activation occurs
in peripheral organs, a signal is transmitted to the brain in
several ways, including cytokines that cross the blood-brain
barrier through saturable transporters, humoral transmission via
the circumventricular organs, and neural transmission via the
afferent nerves (e.g., the vagal nerve) that innervate the site
in the periphery, where the inflammatory response occurred.
This signal ultimately results in the synthesis and release of
pro-inflammatory cytokines in the brain by activated astrocytes,
microglia, vascular endothelial cells, and fibroblasts (Licinio and
Wong, 1997; Miller et al., 1999; Dantzer, 2007; Capuron and
Miller, 2011; Lampron et al., 2013). Cytokine receptors are
present in the brain, and they are activated, in most cases, not
by peripheral cytokines that enter the brain, but by cytokines
that are produced locally in the brain in response to peripheral
cytokines. These locally produced cytokines act on other glial
cells, and ultimately, on neurons (Dantzer, 2007). In addition to
their role in the elaboration of the central component of the acute
phase inflammatory response, cytokines are also involved in
brain development and neuronal plasticity (Dantzer, 2007). Some
cytokines diminish the functional capacity of GRs, which directly
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contributes to insufficient glucocorticoid signaling. Cytokine
administration in vivo and in vitro has been shown to reduce both
GR number and function (Leonard and Myint, 2009).
The functions of the HPA axis and the immune system
are mutually dependent (Haddad et al., 2002; Haddad, 2008;
Leonard and Myint, 2009; Miller et al., 2009). Cortisol inhibits
CRH production in the hypothalamus and ACTH production in
the pituitary gland (Figure 6). In the periphery, cortisol binds
to intracellular receptors in peripheral immune cells. These
cortisol/receptor complexes translocate to the nucleus and inhibit
the immune response in two ways. First, they interact with other
transcription factors to abolish cytokine production; second, they
directly bind to DNA to stimulate gene transcription, which
produces inhibitors that act as anti-inflammatory factors. On
the other hand, certain pro-inflammatory cytokines, such as
interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-a, are
potent stimulators of CRH, and therefore, they stimulate the
HPA axis. These pro-inflammatory cytokines are produced in
the periphery by a variety of immune cells, such as activated
monocytes, macrophages, T-cells, B-cells, natural killer cells, and
fibroblasts, in response to different stimuli, including pathogen-
associated molecules, danger signals, and stress. It has been
postulated that pro-inflammatory cytokine activation of CRH
pathways forms the basis of the HPA axis overactivity in
depression. Thus, this pathway represents a primary mechanism
by which cytokines contribute to the development of depression
(Müller and Ackenheil, 1998; Haddad et al., 2002; Leonard and
Myint, 2009).
The interaction between cytokines and glucocorticoids during
a stress response is complex (Figure 6). On one hand, stress
can directly activate the peripheral immune system, and on the
other hand, stress inhibits the peripheral immune response by
activating the HPA axis and the sympathetic nervous system.
Peripheral pro-inflammatory cytokines activate the release of
brain cytokines, which then activate neuronal circuits and the
HPA axis. Glucocorticoids inhibit the release or function of these
pro-inflammatory cytokines, and they also inhibit the HPA axis
through a negative feedback loop.
This brings us to the neuro-immune hypothesis of depression.
In 1977, Bartrop et al. (1977) pioneered the concept of the
psycho-neuroimmunology of depression. They were the first
to hypothesize that severe psychological stress might produce
measurable abnormalities in immune function, which could not
be explained by hormonal changes. Since that time, studies have
shown that MDD is often accompanied by chronic inflammatory
changes (Leonard, 2005, 2006, 2007, 2014; Leonard and Myint,
2006a,b; Leonard and Myint, 2009).
An essential component in the neuro-immune hypothesis
of depression is that patients with depression exhibit elevated
levels of CRH. This neuropeptide orchestrates the stress-induced
activation of the HPA axis (with the release of ACTH and
cortisol), activates the locus coeruleus (behavioral component)
(Valentino and Foote, 1988), and stimulates the sympathetic
nervous system (and release of catecholamines) (Tsatsanis
et al., 2007). Stress leads to the activation of macrophages
in the blood and microglia in the brain, which results in
the release of pro-inflammatory cytokines. This stress-induced
release represents one of the primary mechanisms by which
cytokines may contribute to the development of depression
(Leonard, 2006, 2007, 2014). These findings supported the
notion that chronic inflammation may be a central factor in
the pathogenesis of MDD. Pro-inflammatory cytokines stimulate
the production of neurotoxic substances (by stimulating the
tryptophan-kynurenine pathway), induce specific inflammatory
changes (iNOS and COX2 activation), and cause hypersecretion
of cortisol. Cortisol inhibits protein synthesis, which reduces the
production of anti-inflammatory and neurotrophic factors. The
final result is the emergence of structural neuronal alterations,
in particular, hippocampal neuronal cell loss. According to
this hypothesis, depression leads to structural changes that
can be considered neurodegenerative, and this condition
may progress into Alzheimer’s disease and other dementias.
Serotonin may offer protection against this damaging influence.
Serotonin appears to have a substantial impact on normal
CNS development and function (Sodhi and Sanders-Bush,
2004). Serotonin acts as a growth factor during embryogenesis;
serotonin receptor activity is a crucial part of the events that lead
to changes in brain structure. In addition, the serotonergic system
interacts with BDNF, which might explain why antidepressant
drugs increase BDNF signaling (Castrén, 2004a,b). It has
been suggested that antidepressant drugs have chronic effects
associated with the repair, and possible reconstruction, of
neuronal networks (Castrén, 2004a,b; Castrén et al., 2007).
Antidepressants are known to enhance axonal and dendritic
sprouting, and they are believed to stabilize synaptic contacts
(Leonard, 2007). Thus, antidepressant drugsmay protect neurons
from detrimental changes by promoting repair and construction
or reconstruction of neuronal networks.
The neuro-immune hypothesis on the pathogenesis of
depression remains indefinite. Several possible theories can
explain how activating the CNS immune system causes
functional changes in the CNS. Our explanation of the genesis of
a depressive disorder focuses on the inhibition of hippocampal
function. This inhibition may result in improper stimulation
or disinhibition of the amygdala and/or disinhibition of the
connection with the medial habenula. In addition, cytokines have
a profound influence on neuronal excitability. When these two
events come together in the amygdala, a phenomenon termed
“kindling” may occur. This brings us to the last hypothesis for




The hypothesis of illness progression is often referred to as a
“kindling” hypothesis. This theory holds that, analogous to the
relationship between kindling and convulsions, some stressors
may produce increasing effects over time, which culminate in
a full-blown affective episode (Post, 2007, 2010). For example,
the more often unipolar or bipolar episodes occur, the more
vulnerable one is to recurrences and the development of cognitive
dysfunction (Post et al., 2012). Here, we take this concept a step
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FIGURE 6 | Relationship between the HPA axis and the immune system. The hypothalamic paraventricular nucleus (green) stimulates the production of cortisol
from the adrenal gland (gray); cortisol inhibits the production of pro-inflammatory cytokines by immune cells (white and blue), by the mechanism shown in the inset.
Cortisol also inhibits (−), and pro-inflammatory cytokines activate (+), the paraventricular nucleus. ACTH, adrenocorticotropic hormone; AVP, arginine vasopressin;
CBG, cortisol binding globulin; CRH, corticotropin releasing hormone; GR, glucocorticoid receptor; HSP, heat shock protein; IL-1, interleukin 1; IL-6, interleukin 6;
MDR pump, multidrug resistance protein (P-glycoprotein); TNFα, tumor necrosis factor alpha.
further to provide a potential explanation for the pathogenesis of
depression.
In experimental models, kindling is characterized by a
progressive increase in neuronal activity, as a result of daily
repeated applications of (subluminal) electrical stimuli, typically
in limbic areas, such as the amygdala or the hippocampus (Post,
2004, 2007). The kindling model is used to study both the
development of clinical seizure disorders (e.g., temporal lobe
epilepsy) and the genesis of behavioral disorders (particularly
bipolar mood disorders). Amygdala kindling involves once-
daily, repeated stimulations of the amygdala (typically pulses
with a 1-s duration) at intensities that are below the amygdala
after-discharge threshold. At first, this treatment causes after-
discharges that gradually increase in duration and complexity,
and they begin to spread through the surrounding cortical
regions. Then, when this stimulation is continued, full-blown
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motor seizures begin to occur, and thereafter, seizures start
occurring spontaneously, in the absence of exogenous electrical
stimulation. In the kindling hypothesis, we propose that a
similar progression occurs in depressive disorders, where initial
episodes are triggered by psychosocial stressors, but with enough
repetition, they also begin to emerge spontaneously.
Amygdala-kindling is accompanied by several biochemical
changes involving classical neurotransmitters, neuropeptides,
cytokines, and neurotrophic factors (Figure 7). Some of these
changes are believed to represent a pathophysiological process
that gives rise to the evolution of seizures and others are thought
to reflect adaptive and compensatory changes that result in
transient, anticonvulsant effects (Post, 2004, 2007). The latter
changes comprise the induction or increased expression of
thyrotropin-releasing hormone (TRH), cholecystokinin (CCK),
neuropeptide Y (NPY), and benzodiazepine/GABA receptors.
A key finding, which possibly links the kindling and the
neuro-endocrine hypotheses, is the observation that CRH
plays an important role in the evolution of kindled seizures.
As an excitatory transmitter, CRH operates as the cardinal
CNS transducer of stressful stimuli. Because the amygdala
and hippocampus are rich in neurons that synthesize CRH
or possesses CRH receptors, repeated stimulation of these
receptors can result in limbic seizures (Brunson et al., 1998).
In addition, corticosteroids are known to accelerate electrical
amygdala kindling epileptogenesis (Karst et al., 1999; Taher et al.,
2005; Kumar et al., 2007). This process may be an important
mechanism for stress-induced facilitation of behavioral and
mood disorders. Therefore, both neuronal (CRH) and humoral
(steroid) factors appear to link the endocrine system to the limbic
system.
The influence of cytokines and neurotrophic factors on
depressive disorders is difficult to understand, which perhaps
makes it a more intriguing issue. This issue is difficult even
without considering the complex interactions among these
factors. Their effects are often found to be biphasic and/or very
complex in nature. This is true for the most intensely studied
cytokines (IL-6, TNF-α, and IL-β) and for the less understood
cytokines, e.g., BDNF. The first three cytokines (IL-6, TNF-α,
and IL-β) increase the vulnerability to glutamate excitotoxicity
(causing cell death), but they are also involved in neuroprotection
against cell death (Bernardino et al., 2005a,b). The same is
true for BDNF, which increases neuronal excitability and also
has neuroprotective effects (Binder et al., 2001). Moreover,
BDNF levels decrease in proportion to the severity of both
depressive and manic episodes (Post, 2007). According to the
model described by Post, BDNF appears to play an important
role in both genetic and environmentally-induced vulnerability
to the development of a (bipolar) mood disorder. Insufficient
protection from kindling, due to a fall in BDNF levels, might
induce the development of an affective episode (Post, 2007).
Returning to the kindling hypothesis, a few findings have
supported the illness progression model. As described above,
both corticosteroids and CRH are capable of enhancing
the excitability of neurons in the corticoid amygdala, and
consequently, lower the stimulation threshold. In various parts
of the cortex, these compounds may be able to induce
uncoordinated electrical activity, which finally results in a
convulsion. The vulnerability to kindling in the amygdala was
decreased by an infusion of BDNF (Osehobo et al., 1999;
Barton and Shannon, 2005). In contrast, the other neurotrophic
factors and cytokines may have the opposite effect. Moreover,
because the amygdala lies deep inside the temporal lobe, it is
difficult to demonstrate neurophysiologically in patients that
the amygdala initiates the emotional response by producing
uncoordinated electrical activity that leads to inappropriate,
disproportional emotional reactions. However, BDNF activity
was decreased in the amygdala of female patients with MDD
(Guilloux et al., 2012). Therefore, although we lack hard evidence
to support this hypothesis, the kindling hypothesis for illness
progression may offer an explanation of how the mood disorder
arises. Repeated psychosocial-stressful events can be considered
a normal aspect of life. In normal conditions, the organism
should be capable of adequately dealing with repeated stressors.
However, in conditions where vulnerability is increased, either by
genetic determination and/or by a transient physiological state,
uncoordinated electrical activity may be induced, and the result
is an inappropriate emotional response.
Based on this hypothesis, one would expect that biological
measures with anticonvulsant effects in the amygdala would also
have a therapeutic effect on mood disorders. This expectation
was fulfilled with ECT, which is believed to exert therapeutic
action by delivering potent anticonvulsant activity (Sanacora
et al., 2003). ECT treatment raises the convulsive threshold
substantially (Sackeim et al., 1987). It may be postulated
that this anticonvulsant activity is necessary in the corticoid
amygdala. However, not all anti-kindling treatments result
in antidepressant effects. For example, several anticonvulsant
drugs are primarily active in mania. Their efficacy in treating
“bipolar” and “unipolar” depression is doubtful, at best. Only
ECT appears to be effective in treating both depression and
mania. Moreover, several effective TCA drugs (but not SSRIs)
have the opposite effect; they enhance the vulnerability of
the amygdala to kindling (Ago et al., 2007). This effect may
correspond to their potential for inducing mania and “rapid
cycling” in bipolar disorder, but it does not explain their
therapeutic effects in depression. It supports the hypothesis that
TCA drugs elicit their therapeutic effects in structures other than
the hippocampal/amygdala complex. This brings into question
whether ECT elicits antidepressant activity in the amygdala. Its
effects on the hippocampus/amygdala may be primarily related
to its anti-manic activity, and its antidepressive effects may
occur elsewhere. For example, these latter effects could occur in
the subgenual cingulate cortex (Seminowicz et al., 2004), which
is part of the limbic cortico-striato-thalamo-cortical (CSTC)
re-entry circuit that includes the NAcbS, which regulates the
motivation to escape misery.
INTEGRATION WITH OUR DEPRESSION
MODEL
It can be concluded that neuroplastic changes seem to connect
all five theories on the pathogenesis of depressive disorder.
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FIGURE 7 | Competing pathological and adaptive endogenous responses to kindled seizures. Cellular components are shown for the (upper panel)
proconvulsant and (lower panel) anticonvulsant biochemical (neuroplastic) reactions to a kindled seizure. Increased and decreased biochemical responses result in
augmenting or inhibiting the ability of the neuronal system to display spontaneous electrophysiological activity (reproduced in an adapted form with permission from
the author and publishers of Post, 2007).
Chronic treatment with antidepressants of several different
classes is known to influence the expression of neurotrophic
factors, for example, antidepressants increase BDNF expression
in both animals and patients (Nibuya et al., 1995; Sen et al.,
2008); cortisol and several cytokines have profound neuroplastic
effects; and the disturbed circadian cortisol rhythm may cause
the biological clock mechanism to induce neuroplastic changes.
All these changes might occur during chronic activation of the
stress response, due to continuous stressful circumstances. In
fact, it would make sense for the system to evolve in ways that
improved the chance of survival under difficult living conditions.
This evolution may be accomplished by memorizing a successful
behavioral reaction and the circumstances that activated the
reaction. This behavior can be memorized through an adaptation
in the hardware that initiates and mediates the stress response.
Adaptation of reward-seeking and misery-fleeing behavior
to changing circumstances is essential for maintaining life
and for continuing the existence of the species. The earliest
vertebrate ancestors of humans regulated these behaviors with
a subcortical network that included the forebrain basal ganglia,
forebrain habenula, and motor control centers in addition to
monoaminergic regulation areas in the upper brainstem and
hypothalamus (Robertson et al., 2014; Loonen and Ivanova,
2015). Therefore, it may be hypothesized that these subcortical
structures also possessed the mechanics to adapt to major
transformations in an animal’s biotope. The mechanisms
involved may have been conserved in humans, through the
two NAcbC/NAcbS-containing CSTC re-entry circuits, which
regulate the motivation for misery-fleeing and reward-seeking
behaviors and through the amygdalar-hippocampal connections
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with the hypothalamus and midbrain. It should be recognized
that, with evolution, the entire forebrain of the earliest vertebrates
migrated up into the human amygdalar-hippocampal complex
(Loonen and Ivanova, 2015; Loonen and Ivanova, submitted).
This complex retains direct connections with the hypothalamic
and midbrain control centers, but it also maintains indirect
connections, via the medial and lateral habenula; and these
latter structures have probably retained their regulatory role in
humans.
The stress response is initiated by the amygdala, which
receives stress inhibiting information from the PFC and the
hippocampus. When these structures begin to malfunction, due
to chronic stressful conditions, the stress response reaches an
unusually high level, which results in a mismatch between
misery-fleeing and reward-seeking behaviors. This mismatch
continues as long as the individual cannot escape from the
troubling circumstances. The inability to escape would lead to
dysphoria, rumination, and negative expectations/hopelessness
(due to high activity in the NAcbS-containing CSTC circuit) and
anhedonia, lack of energy, and indecisiveness (due to low activity
in the NAcbC-containing re-entry circuit). This impairment can
be treated with psychotherapy, by increasing the abilities of the
hippocampus and PFC to ease their hyperactive signaling. It can
also be treated with biological treatments by interfering with the
signal that activates the amygdala to induce the disproportionate
stress response, and by directly inhibiting the NAcbS circuit.
The above scenario is supported by the fact that anyone can
get depressed, when the burden of stressful circumstances is
sufficiently intense and continuous. However, it does not explain
why depression is so prevalent in the present era, to the extent
that it may be the third leading cause of disability worldwide
(Kessler, 2012). In our opinion, this high prevalence is partly
due to overactive biological mechanisms that regulate behavioral
adaptation to changes in environmental circumstances. This
type of overactivity may arise from allostatic overload, due to
developmental, ecological, social, and individual physical health
influences (McEwen, 2012, 2015); from genetic and epigenetic
vulnerability; from prolonged exposure time, due to increased
life expectancy; from decreased selection pressure; and from
redundant defensive activity, due to the absence of real threats.
Consequently, we suggest that studies on the epidemiology,
course, and causes of depression should not assume that
depression is an illness; instead, depression should be considered
a general form of reacting that indicates an impairment in the
individual’s adaptation mechanism. The likelihood of becoming
depressed might depend on the individual’s vulnerability to
neuroplastic changes, which may be conferred by genetic factors,
prior experiences, physical diseases, and toxic influences. These
potential sources of vulnerability comprise suggestions for future
research.
Certain components of our anatomical model require
verification. For example, our model indicates the existence of
re-entry circuits that regulate misery-fleeing and reward-seeking
behaviors. To our knowledge, no study has shown that the
fibers running from the thalamus to the subgenual cingulate
cortex contribute to a cortical-subcortical re-entry circuit
(Figure 2).
Moreover, the role of the insular cortex should be further
elucidated. We have hypothesized that this phylogenetically
ancient part of the cerebral cortex plays a critical role in
perceiving feelings of pleasure (satisfaction) and happiness
(euphoria) (Loonen et al., 2016). Indeed, the insular cortex was
demonstrated to be involved in processing emotions, like anger,
fear, happiness, sadness, or disgust, and it has been shown to
display treatment-responsive changes in activity associated with
different mood disorders (Nagai et al., 2007). However, the
exact mechanism of becoming aware of these emotions remains
unclear.
In addition, it may be of interest to identify the human limbic
homolog of the habenula-projecting globus pallidus (GPh) of
lampreys. The lamprey is themodern representative of theearliest
vertebrate ancestors of humans (Loonen and Ivanova, 2015). In
lampreys, the GPh regulates the activity of the lateral habenula,
which in turn, controls the activity of the phylogenetic ancestor
of the VTA (Robertson et al., 2014). In our opinion, the earliest
vertebrate’s striatum and pallium (primitive cortex) later became
integrated with the hippocampal complex and amygdala. The
output of the habenula to monoaminergic centers within the
upper brainstem has been very well conserved during evolution
(Aizawa et al., 2011; Velasquez et al., 2014; Antolin-Fontes et al.,
2015). Similarly, an equivalent of the GPh may play a critical
role in regulating the reward-seeking response. A good candidate
for this GPh-equivalent might be a group of habenula-projecting
neurons within the bed nucleus of the stria terminalis (Loonen
and Ivanova, submitted).
The potential roles of the circuits described in our model can
be investigated in neuroimaging studies, conducted before and
after challenging these circuits with selective pharmacological
and neurotrophic probes. However, because the habenula has a
very limited size and complex structure, even a high-resolution
fMRI approach offers limited possibilities for studying this
structure. Also, animal studies can provide fruitful data, collected
after systemic and local applications of substances. However, this
research should begin by reinterpreting the many existing data,
within the context of our model.
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